(HealthDay News) — Liraglutide is effective as an adjunct to diet and exercise for weight loss in overweight and obese adults, according to a study presented at the annual European Congress on Obesity, held from May 28–31 in Sofia, Bulgaria.
John Wilding, DM, from the University of Liverpool in the United Kingdom, and colleagues examined the 56-week efficacy and safety of 3.0mg liraglutide as an adjunct to diet and exercise. A total of 3,731 overweight and obese adults (mean age, 45.1 years) without type 2 diabetes were randomized in a 2:1 ratio to once-daily subcutaneous liraglutide or placebo plus diet and exercise.
The researchers found that, on all weight loss-related parameters, liraglutide was superior to placebo. In addition, liraglutide improved glycemia, blood pressure, and lipids. Pre-treatment prediabetes status and body mass index did not impact weight loss. Early-onset nausea and diarrhea were the most common adverse events with liraglutide, but most events were mild/moderate and transient. Gallbladder disorders and pancreatitis occurred more frequently with liraglutide than placebo. In both groups, the adverse event withdrawal was less than 10 percent. The safety profile was consistent with that of prior trials with liraglutide.
“Liraglutide 3.0mg, as adjunct to diet and exercise, was efficacious and generally well tolerated,” the authors note in a concluding statement.
One author disclosed financial ties to Novo Nordisk, which funded the study and manufactures liraglutide.